Aquestive Therapeutics (AQST) 10-Q5 May 202020 Q1 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	May 01, 2020
Cover [Abstract]
Entity Registrant Name	Aquestive Therapeutics, Inc.
Entity Central Index Key	0001398733
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		33,582,696
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Address, State or Province	NJ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 35,521	$ 49,326
Trade and other receivables, net	9,536	13,130
Inventories, net	3,087	2,859
Prepaid expenses and other current assets	2,944	2,999
Total current assets	51,088	68,314
Property and equipment, net	9,059	9,726
Right-of-use assets, net	3,912	0
Intangible assets, net and other assets	428	439
Total assets	64,487	78,479
Current liabilities:
Accounts payable and accrued expenses	14,090	17,749
Lease liabilities, current	609	0
Deferred revenue, current	663	806
Total current liabilities	15,362	18,555
Loans payable, net	60,922	60,338
Lease liabilities	3,424	0
Deferred revenue, net of current portion	4,209	4,348
Asset retirement obligations	1,399	1,360
Total liabilities	85,316	84,601
Contingencies (note 18)
Stockholders' deficit:
Common stock, $.001 par value. Authorized 250,000,000 shares; 33,582,696 and 33,562,885 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	34	34
Additional paid-in capital	126,141	124,318
Accumulated deficit	(147,004)	(130,474)
Total stockholders' deficit	(20,829)	(6,122)
Total liabilities and stockholders' deficit	$ 64,487	$ 78,479

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Stockholders' deficit:
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	33,582,696	33,562,885
Common stock, shares outstanding (in shares)	33,582,696	33,562,885

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) [Abstract]
Revenues	$ 8,765	$ 12,643
Costs and expenses:
Manufacture and supply	3,659	3,506
Research and development	4,354	4,303
Selling, general and administrative	14,613	17,908
Total costs and expenses	22,626	25,717
Loss from operations	(13,861)	(13,074)
Other income/(expenses):
Interest expense	(2,771)	(1,926)
Interest income	102	274
Net loss before income taxes	(16,530)	(14,726)
Income taxes	0	0
Net loss	(16,530)	(14,726)
Comprehensive loss	$ (16,530)	$ (14,726)
Net loss per share - basic and diluted (in dollars per share)	$ (0.49)	$ (0.59)
Weighted-average number of common shares outstanding - basic and diluted (in shares)	33,569,694	24,963,603

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of ASU 2014-09 and ASU 2018-07	$ 0	$ 20	$ (2,852)	$ (2,832)
Balance at Dec. 31, 2018	$ 25	71,431	(61,376)	10,080
Balance (in shares) at Dec. 31, 2018	24,957,309
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	$ 0	1,422	0	1,422
Share-based compensation (in shares)	17,830
Net loss	$ 0	0	(14,726)	(14,726)
Balance at Mar. 31, 2019	$ 25	72,873	(78,954)	(6,056)
Balance (in shares) at Mar. 31, 2019	24,975,139
Balance at Dec. 31, 2019	$ 34	124,318	(130,474)	(6,122)
Balance (in shares) at Dec. 31, 2019	33,562,885
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	$ 0	1,823	0	1,823
Share-based compensation (in shares)	19,811
Net loss	$ 0	0	(16,530)	(16,530)
Balance at Mar. 31, 2020	$ 34	$ 126,141	$ (147,004)	$ (20,829)
Balance (in shares) at Mar. 31, 2020	33,582,696

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (16,530)	$ (14,726)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	887	783
Share-based compensation	1,860	1,520
Amortization of debt issuance costs and discounts	584	389
Non-cash interest expense	0	527
All other non-cash expenses	(144)	(45)
Changes in operating assets and liabilities:
Trade receivables and other receivables	3,738	(963)
Inventories, net	(228)	304
Prepaid expenses and other current assets	53	(1,715)
Accounts payable and accrued expenses	(3,575)	(3,306)
Deferred revenue	(282)	(448)
Net cash used for operating activities	(13,637)	(17,680)
Cash flows from investing activities:
Capital expenditures	(131)	(376)
Net cash used for investing activities	(131)	(376)
Cash flows from financing activities:
Payments for taxes on share-based compensation	(37)	(2,609)
Net cash used for financing activities	(37)	(2,609)
Net decrease in cash and cash equivalents	(13,805)	(20,665)
Cash and cash equivalents:
Beginning of period	49,326	60,599
End of period	35,521	39,934
Supplemental disclosures of cash flow information:
Cash payments for interest	2,188	1,009
Net (decrease) in accrued capital expenditures	(84)	(253)
Net increase in financing costs included in accounts payable and accrued expenses	0	311
Accrued withholding tax for share based compensation	$ (1)	$ (4)

Corporate Organization and Comp

Corporate Organization and Company Overview	3 Months Ended
Corporate Organization and Company Overview	Mar. 31, 2020
Corporate Organization and Company Overview [Abstract]
Corporate Organization and Company Overview	Note 1. Corporate Organization and Company Overview (A) Company Overview Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) is a pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs and solve critical healthcare challenges. The Company has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and is developing orally administered complex molecules as alternatives to more invasive therapies. Aquestive is pursuing its business objectives through both in-licensing and out-licensing arrangements, as well as the commercialization of its own products. Production facilities are located in Portage, Indiana, and corporate headquarters, sales and commercialization operations and primary research laboratory facilities are based in Warren, New Jersey. The Company’s major customer and primary commercialization licensee has global operations headquartered in the United Kingdom with principal operations in the United States; other customers are principally located in the United States. Aquestive is subject to risks common to companies in similar industries and stages of development, including, but not limited to, competition from larger companies, reliance on revenue from a limited number of products and customers, adequacy of existing and availability of additional operating and growth capital as and when required, uncertainty of regulatory approval for marketing its product candidates, reliance on a single manufacturing site, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, dependence on patent-protected proprietary technology, ongoing government regulatory compliance requirements, dependence on the clinical and commercial success of its drug candidates, and uncertainty of broad adoption of its approved products, if any, by physicians and consumers. Aquestive is also subject to the risks and uncertainties associated with the COVID-19 pandemic. See Note 4. Risks and Uncertainties for further discussion related to COVID-19. (B) Equity Transaction Equity Offering of Common Stock On December 17, 2019, Aquestive received net proceeds of $37,835 after deducting underwriting discounts of $2,415 for the sale of 8,050,000 shares of common stock in a public offering. Professional fees and other costs of this offering totaled $540, in addition to the underwriting discounts.

Basis of Presentation

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2020
Basis of Presentation [Abstract]
Basis of Presentation	Note 2. Basis of Presentation The accompanying interim unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with Article 10 of Regulation S-X for interim financial reporting. In compliance with those rules, certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes for the fiscal year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the SEC on March 11, 2020 (the “2019 Annual Report on Form 10-K”). As included herein, the condensed consolidated balance sheet at December 31, 2019 is derived from the audited consolidated financial statements as of that date. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results of interim periods have been included. The Company has evaluated subsequent events for disclosure through the date of issuance of the accompanying unaudited condensed financial statements. Any reference in these notes to applicable guidance refers to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2020
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies (A) Principles of Consolidation The interim condensed consolidated financial statements presented herein include the accounts of Aquestive Therapeutics, Inc. and its wholly owned subsidiary, MonoSol Rx, Inc. Other than corporate formation activities, MonoSol Rx, Inc. has conducted no commercial, developmental or operational activities and has no customers or vendors. The results of operations and cash flows reported in these condensed consolidated financial statements should not be regarded as necessarily indicative of results that may be expected in any other interim period or for the entire fiscal year. (B) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to estimates and assumptions include allowances for rebates from proprietary product sales, the allowance for sales returns, the useful lives of fixed assets, valuation of share-based compensation and contingencies. (C) Recent Accounting Pronouncements As an emerging growth company, the Company has elected to take advantage of the extended transition period afforded by the Jumpstart Our Business Startups Act for the implementation of new or revised accounting standards and, as a result, the Company will comply with new or revised accounting standards no later than the relevant dates on which adoption of such standards is required for emerging growth companies. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Recently Adopted Accounting Pronouncements: In February 2016, the Financial Accounting Standards Board issued ASU 2016-02, Leases (Topic 842) , and issued amendments in July 2018 provided by ASU 2018-10. This ASU, as amended, requires lessees to recognize lease assets, termed “right-of-use assets” and related lease liabilities on the balance sheet that had previously been classified as operating leases under prior authoritative guidance. For income statement purposes, leases are now required to be classified as either operating or financing leases under a dual model similar to that specified by ASC 840. Operating leases continue to result in straight-line expense while financing leases result in a front-loaded expense pattern in a manner similar to recognition of capital lease expenses under ASC 840. The Company adopted ASU 2016-02 on January 1, 20 20 using the modified retrospective transition provisions of ASC 842 to leases in effect as of that date of adoption, and recorded lease liabilities and right-of-use assets, as adjusted for accrued lease payments, in the amount of $4,2 based on an estimated incremental borrowing rate of 16.9%, representing the present value of remaining minimum lease payments. The assets and liabilities thus recorded were primarily those related to the Company’s leased plant, laboratory and corporate administrative facilities. The Company elected to apply the ASU-specified practical expedients and accordingly did not re-assess (i) whether its contracts contained a lease under the new definition of a lease, (ii) the classification of those leases and (iii) initial direct costs of existing leases. In addition, the Company elected not to apply the hindsight expedient in the assessment of lease renewals and resultant term of leases. The Company also elected not to recognize a right-of-use asset and lease liability for those leases with a remaining lease term of 12 months or less. The adoption of ASU 2016-02 did not require a cumulative-effect adjustment to the opening balance of the accumulated deficit at the time of adoption. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework. In November 2018, the FASB issued ASU 2018-18, C ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, Recent Accounting Pronouncements Not Adopted as of March 31, 2020: In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other Internal-Use Software (Subtopic 350-40: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update provides guidance distinguishing between capitalizable service contract implementation costs and contract costs required to be expense. In addition, the update requires that the term of the hosting arrangement is to include the non-cancelable period of the arrangement plus periods covered by (i) an option to extend the arrangement if the customer is reasonably certain to exercise that option; (ii) an option to terminate the arrangement if the customer is reasonably certain not to exercise the termination option and (iii) an option to extend (or not to terminate) the arrangement in which exercise of the option is in the control of the vendor. This standard will become effective for the Company beginning January 1, 2021. The amendments may be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company is currently evaluating the impact of ASU 2018-15 on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, which amends accounting for income taxes during interim periods and makes changes to certain income tax classifications. The new standard allows exceptions to the use of the incremental approach for intra-period tax allocation, when there is a loss from continuing operations and income or a gain from other items, and to the general methodology for calculating income taxes in an interim period, when a year-to-date loss exceeds the anticipated loss for the year. The standard also requires franchise or similar taxes partially based on income to be reported as income tax and the effects of enacted changes in tax laws or rates to be included in the annual effective tax rate computation from the date of enactment. The standard will be effective for the Company beginning January 1, 2022, with early adoption of the amendments permitted. The Company is currently evaluating the impact from the adoption of ASU 2019-12 on its consolidated financial statements Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or not significant to the condensed consolidated financial statements of the Company.

Risks and Uncertainties

Risks and Uncertainties	3 Months Ended
Risks and Uncertainties	Mar. 31, 2020
Risks and Uncertainties [Abstract]
Risks and Uncertainties	Note 4. Risks and Uncertainties The Company’s cash requirements for 2020 and beyond include expenses related to continuing development and clinical evaluation of its products, costs of regulatory filings, patent prosecution expenses and litigation expenses, expenses related to commercialization of its products, as well as costs to comply with the requirements of being a public company. As of March 31, 2020, working capital (current assets minus current liabilities) totaled $35,726, which included $35,521 of cash and cash equivalents. As of March 31, 2020, Aquestive has experienced a history of net losses and the Company’s accumulated deficits totaled $147,004, which have been partially funded by profits from manufacture and supply operations, licensing revenues and certain other services, with the balance of the related funding requirements met by the Company’s equity and debt securities offerings and 12.5% Senior Secured Notes due 2025. In 2019, the Company raised funding totaling $52,226, consisting of net proceeds of $13,110 from the refinancing of its debt in July, $37,295 from the public offering of 8,050,000 common shares in December 2019, and $1,821 from the exercise of warrants issued in connection with the aforementioned debt refinancing. In addition to the characteristics described above, the nature of which provide indications that the Company’s ability to execute its near-term business objectives and achieve profitability over the longer term cannot be assured, management views the impact of COVID-19 on the economy, its industry and its own operations as rapidly evolving, the future effects of which are highly uncertain and currently unpredictable. Due to current or future interruptions and possible disruptions in health services, FDA operations, freight and other transportation services, supply, manufacturing, workforce health, availability of favorable financial markets and other essential human and business requirements, the possibility exists that the severity, rapidity of the spread, and the duration of the COVID-19 pandemic may be expected to negatively affect such areas as pre-clinical and clinical trials of our product candidates, regulatory review and approval of our product candidates, customer demand for our products and services, our customers’ ability to pay for goods and services, uninterrupted supply of pharmaceutical ingredients and other raw materials from our approved vendors, ongoing availability of an appropriate labor force and skilled professionals, and additional capital from debt or equity investors. Subject to and absent any material adverse effect of these and other possible COVID-19 effects, the Company expect s that its anticipated revenues from licensed and proprietary products, cash on hand and the funds received from the equity offering, potential monetization of its out-licensed apomorphine product candidate, subject to regulatory approval which cannot be assured, and access to the capital markets under its shelf registration statement, w ould be adequate to meet expected operating, investing, and financing needs for the next twelve months. To the extent additional funds are necessary to meet liquidity needs as the Company continues to execute its business strategy, the Company anticipates that additional funding requirements will be obtained through monetization of certain royalty streams or through availability of additional debt or equity financings, and continuing expense reduction initiatives, or a combination of these potential sources of funds, although the Company can provide no assurance that these sources of funding will be available on reasonable terms, if at all , and we could be required to utilize available financial resources sooner than expected . We have based this expectation on assumptions that could change or prove to be inaccurate , either due to the impact of COVID-19 or to unrelated factors including factors arising in the capital markets, asset monetization markets, regulatory approval process, regulatory oversight and other factors.

Revenues and Trade Receivables,

Revenues and Trade Receivables, Net	3 Months Ended
Revenues and Trade Receivables, Net	Mar. 31, 2020
Revenues and Trade Receivables, Net [Abstract]
Revenues and Trade Receivables, Net	Note 5. Revenues and Trade Receivables, Net Our revenues to date have been earned from our product development pipeline, marketed product activities and self-developed medicines. These activities generate revenues in four primary categories: manufacturing and supply revenue, co-development and research fees, license and royalty revenue, and proprietary product sales, net. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the current revenue standard. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. At contract inception, we assess the goods promised in our contracts with customers and identify a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying our performance obligations, we consider all goods or services promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders or invoices. The Company’s performance obligation with respect to its proprietary product sales is satisfied at a point in time which transfers control upon delivery of the product to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time. With respect to manufacturing and supply revenue stream, a quantity is ordered and manufactured according to customer’s specifications and represents a single performance obligation. The products manufactured are exclusively for specific customers and have no alternative use. Under the customer arrangements, the Company is entitled to receive payments for progress made to date once the acceptance requirements surrounding quality control are satisfied. Thus, revenues related to this product stream are recognized at the point in time when the manufactured product passes quality control. Royalty revenues are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold to the Company’s strategic partners, as all royalties are directly attributable to the Company’s manufacturing activities, and are therefore recognizable at the same time the manufacturing revenue is recognizable. In addition to usage-based royalties, licensing contracts may contain provisions for one-time payments related to certain license fees and milestone achievements. Revenue recognition of these license fees and milestone payments depend on the nature of the specific contract; typically license and milestone payments are recognized at a point in time in the period they are achieved. However, there are limited instances where upon review of the contract, it is determined that the license is non-distinct and limited in nature and does not provide benefit to the customer without purchasing the product, these upfront licensing fees are recognized over time (typically the length of the contract). Co-development and research fee revenue is recorded over time based upon the progress of services provided in order to complete the specific performance obligation identified in the related contract. Revenues from sale of products and services and the subsequent related payments are evidenced by a contract with the customer, which includes all relevant terms of sale. For manufacturing and supply and proprietary product sales, invoices are generally issued upon the transfer of control and co-development and research revenue is typically invoiced based on the contractual payment schedule, or upon completion of the service. Invoices are typically payable 30 to 60 days after the invoice date, however some payment terms may reach 105 days depending on the customer. The Company performs a review of each specific customer’s creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers’ creditworthiness prospectively. Contract Assets In limited situations, certain customer contractual payment terms require us to bill in arrears; thus, we satisfy some, or all, of our performance obligations before we are contractually entitled to bill the customer. In these situations, billing occurs subsequent to revenue recognition, which results in a contract asset. We reflect these contract assets as a component of other receivables within Trade and other receivables on the Condensed Consolidated Balance Sheet. As of March 31, 2020, and December 31, 2019, such contract assets were $1,458, and $4,363, respectively. Contract Liabilities In other limited situations, certain customer contractual payment terms allow us to bill in advance; thus, we receive customer cash payment before satisfying some or all of our performance obligations. In these situations, billing occurs in advance of revenue recognition, which results in contract liabilities. We reflect these contract liabilities as deferred revenue on our Consolidated Balance Sheet. As we satisfy our remaining performance obligations, we release a portion of the deferred revenue balance. As of March 31, 2020, and December 31, 2019, such contract liabilities were $4,872 and $5,154, respectively. The Company’s revenues were comprised of the following: Three Months Ended March 31, 2020 2019 Manufacture and supply revenue $ 6,916 $ 6,669 License and royalty revenue 426 4,622 Co-development and research fees 263 770 Proprietary product sales, net 1,160 582 Total revenues $ 8,765 $ 12,643 Disaggregation of Revenue The following table provides disaggregated net revenue by geographic area: Three Months Ended March 31, 2020 2019 United States $ 7,506 $ 12,394 Ex-United States 1,259 249 Total revenues $ 8,765 $ 12,643 Non-United States revenues is derived primarily from products manufactured for the Australian and Malaysian markets. Trade and other receivables, net consist of the following: March 31, December 31, 2020 2019 Trade receivables $ 8,470 $ 9,094 Contract and other receivables 1,406 4,363 Less: allowance for bad debt (84 ) (124 ) Less: sales-related allowances (256 ) (203 ) Trade and other receivables, net $ 9,536 $ 13,130 Other receivables totaled $1,406 and $4,363 as of March 31, 2020 and December 31, 2019, respectively, consisting primarily of reimbursable costs incurred on behalf of customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services. Sales-related allowances for both periods presented are estimated in relation to revenues recognized for sales of Sympazan®. The following table presents the changes in the allowance for bad debt: March 31, December 31, 2020 2019 Allowance for doubtful accounts at beginning of period $ 124 $ 58 (Reversals)/additions charged to bad debt expense (40 ) 66 Recoveries from amounts previously reserved -- — Allowance for doubtful accounts at end of period $ 84 $ 124 Sales Related Allowances and Accruals Revenues from sales of products are recorded net of prompt payment discounts, wholesaler service fees, returns allowances, rebates and co-pay support programs. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved. The calculation of some of these items requires management to make estimates based on sales data, historical return data, contracts and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis. The following table provides a summary of activity with respect to our sales related allowances and accruals for the three months ended March 31, 2020: Total Sales Related Allowances and Accruals Balance at December 31, 2019 $ 1,377 Provision related to sales during the period 1,157 Credits and payments (867 ) Balance at March 31, 2020 $ 1,667 Total reductions of gross product sales from sale-related allowances and accruals were $1,157 for the three months ended March 31, 2020. Accruals for returns allowances and prompt pay discounts are reflected as a direct reduction to trade receivable and accruals for wholesaler fees, co-pay cards and rebates as current liabilities. The accrued balances relative to these provisions included in Trade and other receivables, net and Accounts payable and accrued expenses were $256 and $1,411, respectively, at March 31, 2020 and $203 and $1,174, respectively, at December 31, 2019. Concentration of Major Customers Customers are considered major customers when sales exceed 10% of total net sales for the period or outstanding receivable balances exceed 10% of total receivables. For the year ended at December 31, 2019, Indivior, Inc. (“Indivior”) provided 86% of the total revenues for the period, and as of that date, the Company’s outstanding receivable balance from Indivior represented approximately 80% of gross receivables. For the three months ended March 31, 2020, revenues provided by Indivior represented approximately 79% of total revenue, and outstanding accounts receivable due from Indivior represented approximately 63% of gross receivables.

Material Agreements

Material Agreements	3 Months Ended
Material Agreements	Mar. 31, 2020
Material Agreements [Abstract]
Material Agreements	Note 6. Material Agreements Commercial Exploitation Agreement with Indivior In August 2008, the Company entered into a Commercial Exploitation Agreement with Reckitt Benckiser Pharmaceuticals, Inc. (with subsequent amendment collectively, the “Indivior License Agreement”). Reckitt Benckiser Pharmaceuticals, Inc. was later succeeded to in interest by Indivior, Inc. Pursuant to the Indivior License Agreement, the Company agreed to manufacture and supply Indivior’s requirements for Suboxone, a sublingual film formulation, both inside and outside the United States on an exclusive basis. Under the terms of the Indivior License Agreement, the Company is required to manufacture Suboxone in accordance with current Good Manufacturing Practice standards and according to the specifications and processes set forth in the related quality agreements the Company entered into with Indivior. Additionally, the Company is required to obtain Active Pharmaceutical Ingredients (“API”) for the manufacture of Suboxone directly from Indivior. The Indivior License Agreement specifies a minimum annual threshold quantity of Suboxone that the Company is obligated to fill and requires Indivior to provide the Company with a forecast of its requirements at various specified times throughout the year. The Indivior License Agreement provides for payment by Indivior of a purchase price per unit that is subject to adjustment based on our ability to satisfy minimum product thresholds. Additionally, in the event Indivior purchases certain large quantities of Suboxone during a specified period, Indivior will be entitled to scaled rebates on its purchases. In addition to the purchase price for the Suboxone supplied, Indivior is required to make certain single digit percentage royalty payments tied to net sales value (as provided for in the Indivior License Agreement) in each of the United States and in the rest of the world subject to annual maximum amounts and limited to the life of the related United States or international patents. In 2012, Indivior exercised its right to buy out its future royalty obligations in the United States under the Indivior License Agreement. Indivior remains obligated to pay royalties for all sales outside the United States. The Indivior License Agreement contains customary contractual termination provisions, including, with respect to a filing for bankruptcy or corporate dissolution, an invalidation of the intellectual property surrounding Suboxone, or commission of a material breach of the Indivior License Agreement by either party. Additionally, Indivior may terminate the Indivior License Agreement if the U.S. Food and Drug Administration (“FDA”) or other applicable regulatory authority declares the Company’s manufacturing site to no longer be suitable for the manufacture of Suboxone or Suboxone is no longer suitable to be manufactured due to health or safety reasons. The initial term of the Indivior License Agreement was seven years from the commencement date. Thereafter, the Indivior License Agreement automatically renews for successive one-year periods, unless either party provides the other with written notice of its intent not to renew at least one year prior to the expiration of the initial or renewal term. Supplemental Agreement with Indivior On September 24, 2017, the Company entered into an agreement with Indivior, or the Indivior Supplemental Agreement. Pursuant to the Indivior Supplemental Agreement, the Company conveyed to Indivior all existing and future rights in the settlement of various ongoing patent enforcement legal actions and disputes related to the Suboxone product. The Company also conveyed to Indivior the right to sublicense manufacturing and marketing capabilities to enable an Indivior licensed generic buprenorphine product to be produced and sold by parties unrelated to Indivior or Aquestive. Under the Indivior Supplemental Agreement, the Company is entitled to receive certain payments from Indivior commencing on the date of the agreement through January 1, 2023. Once paid, all payments made under the Indivior Supplemental Agreement are non-refundable. Through February 20, 2019, the at-risk launch date of the competing generic products of Dr. Reddy’s Labs and Alvogen, the Company received an aggregate of $40,750 from Indivior under the Indivior Supplemental Agreement, of which $4,250 was collected during the three months ended March 31, 2019. Further payments under the Indivior Supplemental Agreement were suspended until adjudication of related patent infringement litigation is finalized. If such litigation is successful, in addition to the amounts already received as described in the foregoing, the Company may receive up to an additional $34,250, consisting of (i) up to $33,000 in the aggregate from any combination of (a) performance or event-based milestone payments and (b) single digit percentage royalties on net revenue earned by Indivior on sales of Suboxone and (ii) an additional $1,250 that was earned through the issuance of additional process patent rights to the Company. The aggregate payments under this Indivior Supplemental Agreement are capped at $75,000. All payments made by Indivior to the Company pursuant to the Indivior Supplemental Agreement are in addition to, and not in place of, any amounts owed by Indivior to the Company pursuant to the Indivior License Agreement. Indivior’s payment obligations under the Indivior Supplemental Agreement are subject to certain factors affecting the market for Suboxone and may terminate prior to January 1, 2023 in the event certain contingencies relating to such market occur. License Agreement with Sunovion Pharmaceuticals, Inc. In April 2016, we entered into a license agreement with Cynapsus Therapeutics Inc. (which was later succeeded to in interest by Sunovion Pharmaceuticals, Inc., or “Sunovion”) referred to as the Sunovion License Agreement, pursuant to which we granted Sunovion an exclusive, worldwide license (with the right to sub-license) to certain intellectual property, including existing and future patents and patent applications, covering all oral films containing APL-130277 (apomorphine) for the treatment of off episodes in Parkinson’s disease patients, as well as two other fields. Our licensee, Sunovion, as sponsor of APL-130277, submitted a New Drug Application (“NDA”) to the FDA on March 29, 2018. According to public statements by Sunovion, following the January 2019 PDUFA date, Sunovion received a Complete Response Letter from the FDA which requires additional data, but does not require additional clinical studies. In the 2019 fourth quarter, Sunovion announced that it had received from the FDA a Prescription Drug User Fee Act (PDUFA) date of May 21, 2020 after the submission of its NDA. In consideration for the rights granted to Sunovion under the Sunovion License Agreement, the Company received aggregate payments totaling $18,000 to date. In addition to the upfront payment of $5,000, the Company also earned an aggregate of $13,000 in connection with specified regulatory and development milestones in the United States and Europe (the “Initial Milestone Payments”), all of which of which has been received to date. No payments were received during the three-month period ended March 31, 2020 and 2019, respectively. The Company is also entitled to receive certain contingent one-time milestone payments related to product availability and regulatory approval in the United States and Europe, certain one-time milestone payments based on the achievement of specific annual net sales thresholds of APL-130277, and ongoing mid-single digit percentage royalty payments related to the net sales of APL-130277, (subject to reduction to low-single digit percentage royalty payments in certain circumstances), subject to certain minimum payments. The maximum aggregate milestone payments that may be paid to the Company pursuant to the Sunovion License Agreement is equal to $45,000. With the exception of the Initial Milestone Payments, there can be no guarantee that any such milestones will in fact be met or that additional milestone payments will be payable. Effective March 16, 2020, the Company entered into a first amendment (the “Amendment”) to the License Agreement (the “Agreement”) dated as of April 1, 2016. The Amendment was entered into for the primary purpose of amending the Agreement as follows: (i) including the United Kingdom and any other country currently in the European Union (EU) which later withdraws as a member country in the EU for purpose of determining the satisfaction of the condition triggering the obligation to pay the third milestone due under the Agreement, (ii) extending the date after which Sunovion has the right to terminate the Agreement for convenience from December 31, 2024 to May 31, 2028, (iii) modifying the date the first minimum annual royalty is due to be paid by Sunovion to the Company from January 1, 2020 to April 1, 2020 and (iv) modifying the termination provisions to reflect the Company’s waiver of the right to terminate the Agreement in the event that the licensed product was not commercialized by January 1, 2020. This Sunovion License Agreement will continue until terminated by Sunovion in accordance with the termination provisions of the Amendment to the Sunovion License Agreement. The Sunovion License Agreement continues (on a country-by-country basis) until the expiration of all applicable licensed patents. Upon termination of the Sunovion License Agreement all rights to intellectual property granted to Sunovion to develop and commercialize products will revert to the Company and Sunovion must continue to pay royalties to the Company on each sale of Sunovion's remaining inventory of products commercialized by Sunovion which include apomorphine as their API. Agreement to Terminate CLA with KemPharm In March 2012, the Company entered into an agreement with KemPharm, Inc. (“KemPharm”) to terminate a Collaboration and License Agreement entered into by the Company and KemPharm during April 2011. Under this termination arrangement, the Company has the right to participate in any and all value that KemPharm may derive from the commercialization or any other monetization of KemPharm’s KP-415 and KP-484 compounds or their derivatives. Among these monetization transactions are those related to any business combinations involving KemPharm and collaborations, royalty arrangements, or other transactions from which KemPharm may realize value from these compounds. During September 2019, the Company received $1,000 from its 10% share of milestone payments paid to KemPharm under its licensing of KP-415 and KP-484 to a third party. There can be no guarantee that any such payments will be made in the future. The Company has not received payments under this arrangement during the three-month periods ended at March 31, 2020 and 2019, respectively.

Financial Instruments - Fair Va

Financial Instruments - Fair Value Measurements	3 Months Ended
Financial Instruments - Fair Value Measurements	Mar. 31, 2020
Financial Instruments - Fair Value Measurements [Abstract]
Financial Instruments - Fair Value Measurements	Note 7. Financial Instruments – Fair Value Measurements Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1 – Quoted prices in active markets for identical assets or liabilities. Cash and cash equivalents consisted of cash in bank checking accounts and money market funds which are all Level 1 assets. • Level 2 – Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. The Company currently has no Level 2 assets or liabilities. • Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. As of March 31, 2020 and 2019, respectively, the Company has no Level 3 assets or liabilities. The carrying amounts reported in the balance sheets for trade and other receivables, prepaid and other current assets, accounts payable and accrued expenses, and deferred revenue approximate fair value based on the short-term maturity of these assets and liabilities. The Company granted warrants to certain holders of its Notes in connection with its debt refinancing during 2019. These warrants were valued based on Level 3 inputs and their fair value was based primarily on an independent third-party appraisal prepared as of the grant date consistent with generally-accepted valuation methods of the Uniform Standards of Professional Appraisal Practice, the American Society of Appraisers and the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued Compensation. See Note 14 for further information on these warrants.

Inventories, Net

Inventories, Net	3 Months Ended
Inventories, Net	Mar. 31, 2020
Inventories, Net [Abstract]
Inventories, Net	Note 8. Inventories, Net The components of Inventory, net is as follows: March 31, December 31, 2020 2019 Raw material $ 1,285 $ 1,244 Packaging material 1,101 1,096 Finished goods 701 519 Total inventories, net $ 3,087 $ 2,859

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
Property and Equipment, Net	Mar. 31, 2020
Property and Equipment, Net [Abstract]
Property and Equipment, Net	Note 9. Property and Equipment, Net March 31, December 31, Useful Lives 2020 2019 Machinery 3-15 yrs $ 21,088 $ 21,088 Furniture and fixtures 3-15 yrs 1,203 1,150 Leasehold improvements (a) 21,333 21,333 Computer, network equipment and software 3-7 yrs 2,790 2,787 Construction in progress 1,403 1,412 47,817 47,770 Less: accumulated depreciation and amortization (38,758 ) (38,044 ) Total property and equipment, net $ 9,059 $ 9,726 (a) Leasehold improvements are amortized over the shorter of the lease term or their estimated useful lives. Total depreciation and amortization related to property and equipment was $714 and $736 for the three-month periods ended at March 31, 2020 and 2019, respectively.

Right-of-Use Assets and Lease O

Right-of-Use Assets and Lease Obligations	3 Months Ended
Right-of-Use Assets and Lease Obligations	Mar. 31, 2020
Right-of-Use Assets and Lease Obligations [Abstract]
Right-of-Use Assets and Lease Obligations	Note 10. Right-of-Use Assets and Lease Obligations The Company leases all realty used as its production and warehouse facilities, corporate headquarters, commercialization operations center and research and laboratory facilities. None of these three leases include the characteristics specified in ASC 842, Leases, that require classification as financing leases and accordingly, these leases are accounted for as operating leases . These leases provide remaining terms between 3. years and 6.5 years, including renewal options expected to be exercised to extend the lease periods. Measurement of the operating lease liability reflects an estimated discount rate of 16.9% applied to minimum lease payments, including expected renewals, based on the incremental borrowing rate experienced in the Company’s latest collateralized debt refinancing. For the three months ended March 31, 2020, total operating lease expenses under these leases was $442, including variable lease expenses such as common area maintenance and operating costs totaling $106. Maturities of the Company’s operating lease liabilities are as follows: Remainder of 2020 $ 910 2021 1,287 2022 1,295 2023 944 2024 565 2025 565 2026 424 Total lease payments 5,990 Less: imputed interest (1,957 ) Total operating lease liabilities $ 4,033

Intangible Assets, Net and Othe

Intangible Assets, Net and Other Assets	3 Months Ended
Intangible Assets, Net and Other Assets	Mar. 31, 2020
Intangible Assets, Net and Other Assets [Abstract]
Intangible Assets, Net and Other Assets	Note 11. Intangible Assets, Net and Other Assets The following table provides the components of identifiable intangible assets, all of which are finite lived, and other assets: March 31, December 31, 2020 2019 Purchased technology-based intangible $ 2,358 $ 2,358 Purchased patent 509 509 2,867 2,867 Less: accumulated amortization (2,727 ) (2,714 ) Intangible assets, net 140 153 Other assets, primarily security deposits 288 286 Total Intangible assets, net and other assets $ 428 $ 439 Amortization expense was $13 for each of the three-month periods ended March 31, 2020 and 2019, respectively. During the remaining life of the purchased patent, estimated annual amortization expense is $50 for each of the years from 2020 to 2022.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	3 Months Ended
Accounts Payable and Accrued Expenses	Mar. 31, 2020
Accounts Payable and Accrued Expenses [Abstract]
Accounts Payable and Accrued Expenses	Note 12. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following: March 31, December 31, 2020 2019 Accounts payable $ 10,283 $ 12,274 Accrued compensation 1,929 3,758 Real estate and personal property taxes 370 300 Accrued distribution expenses 1,411 1,174 Other 97 243 Total accounts payable and accrued expenses $ 14,090 $ 17,749

12.5% Senior Secured Notes and

12.5% Senior Secured Notes and Loans Payable	3 Months Ended
12.5% Senior Secured Notes and Loans Payable	Mar. 31, 2020
12.5% Senior Secured Notes and Loans Payable [Abstract]
12.5% Senior Secured Notes and Loans Payable	Note 13. 12.5% Senior Secured Notes and Loans Payable 12.5% Senior Secured Notes On July 15, 2019, the Company completed a private placement of up to $100 million aggregate principal of its 12.5% Senior Secured Notes due 2025 (the “Notes”) and issued warrants for two million shares of common stock (the “Warrants”), $.001 par value per share, through the structuring agent, Morgan Stanley & Co., LLC, and entered into a purchase agreement and related agreements including a Collateral Agreement with U.S. Bank National Association, as trustee and collateral agent, and a Lien Subordination and Intercreditor Agreement for the benefit of Madryn Health Partners, other institutional noteholders and U.S. Bank National Association in dual roles providing terms and governing an asset-based loan facility. Upon closing of the Indenture for such Notes (“Indenture”), the Company issued $70,000 of the principal of the Notes (the “Initial Notes”) along with the Warrants and rights of first offer (the “First Offer Rights”) to the lenders participating in this transaction for Notes and Warrants (the “Lenders”). Issuance of the Initial Notes and Warrants provided net proceeds of $66,082. In addition to the Initial Notes, the Indenture may provide access to further loans of up to $30,000 that may become available in two tranches of Additional Notes tied to the NDA filing for and FDA U.S. marketing approval of Libervant™, an important part of our drug candidate pipeline. Provided that no events of default exist, the Company may elect to, and subject to approval of the holder of a majority of the outstanding principal amount of the Notes, in its discretion, to offer to the Lenders participation in a $10,000 additional offering of 12.5% senior secured notes (the “First Additional Offering”) under terms similar to the Initial Notes, on or before March 31, 2021, upon the filing of the Libervant NDA with the FDA. A second identical funding opportunity would allow the Company to obtain, on or before March 31, 2021, an additional $20,000 if the first option has been elected and funded, or, if not elected or funded, an additional $30,000 may be offered for issuance following FDA approval of Libervant for marketing in the U.S. There can be no assurance that any additional financing will be consummated. Proceeds from issuance of the Initial Notes and Warrants were used to fully repay the Company’s $56,340 outstanding indebtedness to Perceptive Credit Opportunities Fund, LP (the “Perceptive Loan”), related early repayment fees and legal and other fees incurred to obtain the loan. The Notes provide a stated fixed rate of 12.5%, payable quarterly in arrears, with the initial quarterly principal repayment of the Initial Notes due on September 30, 2021, and the final quarterly payment due at maturity on June 30, 2025. Principal payments are scheduled to increase annually from 10% of the face amount of debt then outstanding during the first four quarters to 40% of the initial loan principal during the final four quarters. A debt maturity table is presented below: Remainder of 2020 $ - 2021 3,500 2022 10,500 2023 17,500 2024 24,500 2025 14,000 Total $ 70,000 The Company may elect, at its option, to prepay the Notes at any time at premiums that range from 101.56% of outstanding principal if prepayment occurs on or after the 5 th Collateral for the loan under the Notes consists of a priority lien on substantially all property and assets, including intellectual property, of the Company. This secured obligation provides payment rights that are senior to all existing and future subordinated indebtedness of the Company and provides Lenders with perfected security interests in substantially all of the Company’s assets. In the event that asset-based loans of up to $10,000 (“ABL Facility”) may be obtained, subject receivables and inventory assets will provide a second priority lien to senior secured Noteholders. The Company’s license of its IP to a third-party drug development enterprise (specifically, Sunovion’s APL-130277 product) is one of the various assets serving as collateral for the loan. The Indenture permits the Company to monetize this asset while specifying that a portion of the proceeds, up to $40,000 if the First Additional Offering has not been elected or funded, or, $50,000 if it has been elected and funded, must be applied to prepay the Initial Notes, at 112.5% of the principal amount of the Notes being repurchased, plus accrued and unpaid interest, if any, thereon, to the date of the repurchase, to the extent elected by the Note holders, assuming that such monetization, up to such $40,000 or $50,000 level, as applicable, equals or exceeds those levels and if such monetization does not equal or exceed such level, such prepayment would pro-rated among the Note holders. To the extent that Lenders do not elect repayment of the debt at the date of the monetization, the amount not elected up to $40,000 (or $50,000 if an additional tranche is issued) will be held in a collateral account until approval of Libervant by the FDA for U.S. marketing, at which time this cash collateral is to be released to the Company. Proceeds in excess of $40,000 (or $50,000 if an additional tranche is issued) can be used immediately for general corporate purposes. As of March 31, 2020, the Company was in compliance with all of its covenants. The Company capitalizes legal and other third-party costs incurred in connection with obtaining debt as deferred debt issuance costs and applies the unamortized portion as a reduction of the outstanding face amount of the related loan in accordance with ASU 2015-03, Interest – Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs Loans Payable - Perceptive In August 2016, the Company entered into a Loan Agreement and Guaranty with Perceptive Credit Opportunities Fund, LP (“Perceptive”) under which the total available facility of $50,000 had been borrowed as of March 2017. At closing, Perceptive received a warrant to purchase senior common equity interests representing 4.5% of the fully diluted common units of the Company on an as converted basis, which was automatically exercised in full at the time of Aquestive’s IPO. In May 2018, the Company and Perceptive agreed to make certain amendments to the loan agreement then in effect that provided for: (1) the postponement of the initial loan principal payment to May 2019, (2) a delay of the loan maturity date to December 16, 2020 and (3) with Perceptive’s consent, an agreement to permit monetization of the royalties and fees that may be derived from sales of certain apomorphine products and a concurrent agreement for the release of the liens related to these royalties and fees. In July 2019, the Perceptive Loan was paid in full in connection with the completion of the sale of the 12.5% Notes and Warrants described above. The early extinguishment of this debt resulted in a charge to third quarter 2019 earnings of an amount of $4,896, including an early retirement premium of $2,944 and the remaining balances of the unamortized loan discount and loan acquisition costs.

Warrants Issued to 12.5% Senior

Warrants Issued to 12.5% Senior Secured Noteholders	3 Months Ended
Warrants Issued to 12.5% Senior Secured Noteholders	Mar. 31, 2020
Warrants Issued to 12.5% Senior Secured Noteholders [Abstract]
Warrants Issued to 12.5% Senior Secured Noteholders	Note 14. Warrants Issued to 12.5% Senior Secured Noteholders The Warrants that were issued in conjunction with the 12.5% Senior Secured Notes (the “Notes”) expire on June 30, 2025 and entitle the holders of the Notes to purchase two million shares of the Company’s common stock at $4.25 per share and include specified registration rights. Management estimated the fair value of the Warrants to be $6,800, assisted by an independent third-party appraiser. The fair value of these Warrants is treated as a debt discount, amortizable over the term of the Warrants, with the unamortized loan portion applied to reduce the face amount of the Notes in the Company’s balance sheet. Additionally, since the Warrants issued do not provide warrant redemption or put rights within the control of the holders that could require the Company to make a payment of cash or other assets to satisfy the obligations under the Warrants, except in the case of a “cash change in control”, the fair value attributed to the Warrants is presented in additional-paid in capital in the accompanying Condensed Consolidated Balance Sheets. Certain holders of the Notes exercised Warrants for the purchase of 428,571 shares of common stock, and proceeds totaling $1,821 were received on December 16, 2019. There were no Warrants exercised by the holders of the Notes during the three-month period ended at March 31, 2020.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
Net Loss Per Share	Mar. 31, 2020
Net Loss Per Share [Abstract]
Net Loss Per Share	Note 15. Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares. As a result of the Company’s net losses incurred for the three-month periods ended at March 31, 2020 and 2019, respectively, all potentially dilutive instruments outstanding would have anti-dilutive effects on per-share calculations for this period. Therefore, basic and diluted net loss per share were the same, as reflected below. Three Months Ended at March 31, 2020 2019 Numerator: Net loss $ (16,530 ) $ (14,726 ) Denominator: Weighted-average number of common shares – basic and diluted 33,569,694 24,963,603 Net loss per common share – basic and diluted $ (0.49 ) $ (0.59 ) As of March 31, 2020 and 2019, respectively, the Company’s potentially dilutive instruments included 2,947,192, and 1,732,426 options to purchase common shares and 44,036 and 172,655 unvested RSUs that were excluded from the computation of diluted weighted average shares outstanding because these securities had an anti-dilutive impact due to the losses reported. Similarly excluded as of March 31, 2020 were potentially dilutive warrants for the purchase of 1,571,429 common shares. No such dilutive warrants were issued as of March 31, 2019.

Share-Based Compensation

Share-Based Compensation	3 Months Ended
Share-Based Compensation	Mar. 31, 2020
Share-Based Compensation [Abstract]
Share-Based Compensation	Note 16. Share-Based Compensation The Company recognized share-based compensation in its Condensed Consolidated Statements of Operations and Comprehensive Loss during 2020 and 2019, respectively, as follows: Three Months Ended March 31, Expense classification: 2020 2019 Manufacture and supply $ 63 $ 44 Research and development 182 208 Selling, general and administrative 1,615 1,268 Total share-based compensation expenses $ 1,860 $ 1,520 Share-based compensation from: Restricted stock units $ 464 $ 463 Stock options 1,396 1,057 Employee stock purchase plan — — Total share-based compensation expenses $ 1,860 $ 1,520 Share-Based Compensation Equity Awards The following tables provide information about the Company’s restricted stock units and stock option unit activity during the three months ended March 31, 2020: Restricted Stock Unit Awards (RSUs) Number of Units Weighted Average Grant Date Fair Value Per Share (In thousands) Unvested at December 31, 2019 74 $ 14.64 Granted — — Vested (30 ) 15.03 Forfeited — — Unvested at March 31, 2020 44 $ 14.38 Grant date fair value of shares vested during the period $ 448 Unrecognized compensation costs at March 31, 2020 $ 435 Unrecognized compensation costs related to awards of RSUs are expected to be recognized over a weighted-average period of less than two years. Stock option awards Number of Options Weighted Average Exercise Price (In thousands) Outstanding at December 31, 2019 2,231 $ 10.42 Granted 716 $ 1.60 Exercised, Forfeited, Expired — Outstanding at March 31, 2020 2,947 $ 8.27 Vested or expected to vest at March 31, 2020 2,739 $ 8.28 Exercisable at March 31, 2020 666 $ 12.75 The weighted average grant date fair value of stock options granted during 2020 was $1.26. The fair value of stock options granted were estimated using the Black-Scholes-Merton pricing model based upon the following assumptions: Three Months Ended March 31, 2020 Expected dividend yield None Expected volatility 100% Expected term (years) 6.1 Risk-free interest rate 0.6% - 1.7% During the three months ended March 31, 2020, options were granted with exercise prices ranging from $1.54 to $4.17, and accordingly, given Aquestive’s share price of $2.19 at the close of the Company’s first quarter of 2020, certain shares granted in 2020 provided intrinsic value of $456 at March 31, 2020. As of March 31, 2020, $8,693 of total unrecognized compensation expenses related to non-vested stock options is expected to be recognized over a weighted average period of 2.1 years from the date of grant. Employee stock purchase plan The Company’s Board of Directors adopted the Aquestive Therapeutics, Inc. Employee Stock Purchase Plan (“ESPP”) in June 2018, as amended and restated effective as of January 1, 2019. Rollout of the ESPP began in late 2018, and initial employee purchases are expected to be made in 2019. The Company may offer common stock purchase rights biannually under offerings that allow for the purchase of common stock at the lower of 85% of the fair value of shares on either the first or last day of the offering period. No purchases under the ESPP occurred in the three months ended March 31, 2020 and 2019, respectively.

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2020
Income Taxes [Abstract]
Income Taxes	Note 17. Income Taxes The Company has accounted for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as net operating loss carryforwards and research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax asset will not be realized. The Company has considered the impact of the CARES Act in relation to the 2020 income tax provision, however due to the full valuation allowance and no ability or intent to carryback the 2020 net operating loss, there is no impact. The Company’s tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items. For the three months ended March 31, 2020 and 2019, the Company recorded no income tax benefit from its pretax losses of $16,530 and $14,726, respectively, due to realization uncertainties. The Company’s U.S. Federal statutory rate is 21%. The primary factor impacting the effective tax rate for the three months ended March 31, 2020 is the anticipated full year operating loss which will require full valuation allowances against any associated net deferred tax assets.

Contingencies

Contingencies	3 Months Ended
Contingencies	Mar. 31, 2020
Contingencies [Abstract]
Contingencies	Note 18. Contingencies (A) Litigation and Contingencies From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of business, including product liability, intellectual property, commercial litigation or environmental or other regulatory matters. Except as described below, Aquestive is not presently a party to any litigation or legal proceedings that is believed to be material. Patent-Related Litigation Beginning in August 2013, we were informed of abbreviated new drug application (“ANDA”) filings in the United States by Watson Laboratories, Inc. (now Actavis Laboratories, Inc., or “Actavis”), Par Pharmaceutical, Inc. (“Par”), Alvogen Pine Brook, Inc. (“Alvogen”), Teva Pharmaceuticals USA, Inc. (“Teva”), Sandoz Inc. (“Sandoz”), and Mylan Technologies Inc. (“Mylan”), for the approval by the FDA of generic versions of Suboxone Sublingual Film in the United States. We filed patent infringement lawsuits against all six generic companies in the United States District Court for the District of Delaware (the “Delaware District Court”). After the commencement of the ANDA patent litigation against Teva, Dr. Reddy’s Laboratories (“DRL”) acquired the ANDA filings for Teva’s buprenorphine and naloxone sublingual film that are at issue in these trials. Of these, cases against three of the six generic companies have been resolved. • Mylan Sandoz • All cases against Par • Actavis • DRL Alvogen Teva Subsequent to the above, all potential generic competitors without a settlement agreement were also sued for infringement of two additional new patents that contain new claims not adjudicated in the original Delaware District Court case against DRL and Alvogen. On July 12, 2019, the Federal Circuit affirmed the decisions from the previously decided cases. The remaining case against Actavis was dismissed in light of the infringement ruling above, which prevents Actavis from entering the market until 2024. The case(s) against the remaining defendants regarding the additional asserted patents have not been finally resolved. A Markman Markman On February 19, 2019, the Federal Circuit issued its mandate reversing the New Jersey District Court’s preliminary injunction against Dr. Reddy’s. Following issuance of the mandate, the New Jersey District Court vacated preliminary injunctions against both Dr. Reddy’s and Alvogen. Dr. Reddy’s, Alvogen, and Mylan all launched generic versions of Suboxone Sublingual Film, and the launches by Dr. Reddy’s and Alvogen are “at risk” because the products are the subject of the ongoing patent infringement litigations. On March 22, 2019, we and Indivior brought suit against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex Inc.in the United States District Court for the Southern District of Florida (the “Southern District of Florida Court”) for infringement of the Company’s U. S. Patent Nos. 8,017,150, 9,687,454, the ’514 patent and ’305 patent, seeking an injunction and potential monetary damages. Following a negotiated settlement between all parties, on December 3, 2019, the parties submitted a Notice of Settlement and a Joint Motion to Approve Consent Judgment. The Southern District of Florida Court entered an order dismissing the suit on December 18, 2019. We are also seeking to enforce our patent rights in multiple cases against BioDelivery Sciences International, Inc. (“BDSI”). Three cases are currently pending but stayed in the U.S. District Court for the Eastern District of North Carolina (the “Eastern District of North Carolina Court”): • The first, a declaratory judgment action brought by BDSI against Indivior and Aquestive, seeks declarations of invalidity and non-infringement of U.S. Patents Nos. 7,897,080, 8,652,378 and 8,475,832. This case is stayed pending final resolution of the above-mentioned appeals on related patents. • The second was filed by us and Indivior related to BDSI’s infringing Bunavail product, and alleges infringement of our patent, U.S. Patent No. 8,765,167, or the ’167 patent, and seeks an injunction and potential monetary damages. Shortly after the case was filed, BDSI filed four (4) IPR’s challenging the asserted ’167 patent. On March 24, 2016, the United States Patent Trial and Appeal Board (“PTAB”), issued a final written decision finding that all claims of the ’167 patent were valid. The case was stayed in May 2016 pending the final determination of the appeals on those decisions. Following the PTAB’s February 7, 2019 decisions on remand denying institution, we and Indivior submitted a notice to the Court on February 15, 2019 notifying the Court that the stay should be lifted as a result of the PTAB’s decisions. We are awaiting further action from the Court. • On January 13, 2017, we also sued BDSI asserting infringement of the ’167 patent by BDSI’s Belbuca product and seeking an injunction and potential monetary damages. On August 7, 2019, the Eastern District of North Carolina Court granted BDSI’s motion to dismiss the Complaint without prejudice and denied BDSI’s motion to stay as moot. On November 11, 2019, we filed a new Complaint against BDSI in the Eastern District of North Carolina Court. On November 27, 2019, BDSI filed a motion to stay the case pending BDSI’s appeal of the PTAB’s remand decisions, and we opposed the motion. The Eastern District of North Carolina Court denied BDSI’s motion to stay on April 1, 2020. BDSI’s appeal of the PTAB’s remand decisions to the United States Court of Appeals for the Fourth Circuit (the “Federal Fourth Circuit Court”) was docketed on March 13, 2019, and on March 20, 2019, we moved to dismiss the appeal for lack of jurisdiction. On August 29, 2019, the Federal Fourth Circuit Court granted the motion to dismiss BDSI’s appeal. On September 30, 2019, BDSI filed a petition for rehearing in the Federal Fourth Circuit Court en banc en banc Antitrust Litigation On September 22, 2016, forty-one states and the District of Columbia, or the States, brought suit against Indivior and us in the U.S. District Court for the Eastern District of Pennsylvania, alleging violations of federal and state antitrust statutes and state unfair trade and consumer protection laws relating to Indivior’s launch of Suboxone Sublingual Film in 2010 and seeking an injunction, civil penalties, and disgorgement. After filing the suit, the case was consolidated for pre-trial purposes with the In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation Daubert California Complaint On December 5, 2019, Neurelis Inc. (“Neurelis”) filed a complaint against Aquestive in the Superior Court of California, County of San Diego alleging Unfair Competition, Defamation, and Malicious Prosecution related to the Company’s pursuit of FDA approval for Libervant™. Neurelis filed a First Amended Complaint on December 9, 2019, alleging the same three causes of action. The Company filed a Motion to Strike Neurelis’s Complaint under California’s anti-SLAPP (“strategic lawsuit against public participation”) statute on Friday, January 31, 2020, which Neurelis is expected to oppose. Neurelis filed a motion for leave to file a Supplemental Complaint on February 5, 2020, which we will oppose. A hearing on our anti-SLAPP motion and Neurelis’s motion for leave was scheduled for April 24, 2020 but was postponed as a result of court closures in San Diego County, California resulting from the COVID-19 pandemic. The parties are awaiting further action from the court regarding a new hearing date.

Subsequent Event

Subsequent Event	3 Months Ended
Subsequent Event	Mar. 31, 2020
Subsequent Event [Abstract]
Subsequent Event	Note 19. Subsequent Event Federal Paycheck Protection Loan On April 17, 2020, the Company was awarded a loan under the federal Paycheck Protection Program (“PPP”) created under the CARES Act in response to the global COVID-19 pandemic. The Company received a $4.8 million loan (the “PPP Loan”) which carried a 1% interest rate payable in 2.5 years. On April 23, 2020, the U.S. Small Business Administration issued revised guidelines which we view as establishing a strong presumption that publicly traded companies are not eligible to receive funding under the PPP. Despite qualifying under the PPP program rules and having been granted the loan, given the revised guidance and the implications of possibly not meeting changing criteria for qualification, we returned our PPP Loan on May 4, 2020.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
Basis of Presentation (Policies)	Mar. 31, 2020
Basis of Presentation [Abstract]
Basis of Presentation	The accompanying interim unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with Article 10 of Regulation S-X for interim financial reporting. In compliance with those rules, certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes for the fiscal year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the SEC on March 11, 2020 (the “2019 Annual Report on Form 10-K”). As included herein, the condensed consolidated balance sheet at December 31, 2019 is derived from the audited consolidated financial statements as of that date. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results of interim periods have been included. The Company has evaluated subsequent events for disclosure through the date of issuance of the accompanying unaudited condensed financial statements. Any reference in these notes to applicable guidance refers to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2020
Summary of Significant Accounting Policies [Abstract]
Principles of Consolidation	(A) Principles of Consolidation The interim condensed consolidated financial statements presented herein include the accounts of Aquestive Therapeutics, Inc. and its wholly owned subsidiary, MonoSol Rx, Inc. Other than corporate formation activities, MonoSol Rx, Inc. has conducted no commercial, developmental or operational activities and has no customers or vendors. The results of operations and cash flows reported in these condensed consolidated financial statements should not be regarded as necessarily indicative of results that may be expected in any other interim period or for the entire fiscal year.
Use of Estimates	(B) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to estimates and assumptions include allowances for rebates from proprietary product sales, the allowance for sales returns, the useful lives of fixed assets, valuation of share-based compensation and contingencies.
Recent Accounting Pronouncements	(C) Recent Accounting Pronouncements As an emerging growth company, the Company has elected to take advantage of the extended transition period afforded by the Jumpstart Our Business Startups Act for the implementation of new or revised accounting standards and, as a result, the Company will comply with new or revised accounting standards no later than the relevant dates on which adoption of such standards is required for emerging growth companies. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Recently Adopted Accounting Pronouncements: In February 2016, the Financial Accounting Standards Board issued ASU 2016-02, Leases (Topic 842) , and issued amendments in July 2018 provided by ASU 2018-10. This ASU, as amended, requires lessees to recognize lease assets, termed “right-of-use assets” and related lease liabilities on the balance sheet that had previously been classified as operating leases under prior authoritative guidance. For income statement purposes, leases are now required to be classified as either operating or financing leases under a dual model similar to that specified by ASC 840. Operating leases continue to result in straight-line expense while financing leases result in a front-loaded expense pattern in a manner similar to recognition of capital lease expenses under ASC 840. The Company adopted ASU 2016-02 on January 1, 20 20 using the modified retrospective transition provisions of ASC 842 to leases in effect as of that date of adoption, and recorded lease liabilities and right-of-use assets, as adjusted for accrued lease payments, in the amount of $4,2 based on an estimated incremental borrowing rate of 16.9%, representing the present value of remaining minimum lease payments. The assets and liabilities thus recorded were primarily those related to the Company’s leased plant, laboratory and corporate administrative facilities. The Company elected to apply the ASU-specified practical expedients and accordingly did not re-assess (i) whether its contracts contained a lease under the new definition of a lease, (ii) the classification of those leases and (iii) initial direct costs of existing leases. In addition, the Company elected not to apply the hindsight expedient in the assessment of lease renewals and resultant term of leases. The Company also elected not to recognize a right-of-use asset and lease liability for those leases with a remaining lease term of 12 months or less. The adoption of ASU 2016-02 did not require a cumulative-effect adjustment to the opening balance of the accumulated deficit at the time of adoption. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework. In November 2018, the FASB issued ASU 2018-18, C ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, Recent Accounting Pronouncements Not Adopted as of March 31, 2020: In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other Internal-Use Software (Subtopic 350-40: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update provides guidance distinguishing between capitalizable service contract implementation costs and contract costs required to be expense. In addition, the update requires that the term of the hosting arrangement is to include the non-cancelable period of the arrangement plus periods covered by (i) an option to extend the arrangement if the customer is reasonably certain to exercise that option; (ii) an option to terminate the arrangement if the customer is reasonably certain not to exercise the termination option and (iii) an option to extend (or not to terminate) the arrangement in which exercise of the option is in the control of the vendor. This standard will become effective for the Company beginning January 1, 2021. The amendments may be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company is currently evaluating the impact of ASU 2018-15 on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, which amends accounting for income taxes during interim periods and makes changes to certain income tax classifications. The new standard allows exceptions to the use of the incremental approach for intra-period tax allocation, when there is a loss from continuing operations and income or a gain from other items, and to the general methodology for calculating income taxes in an interim period, when a year-to-date loss exceeds the anticipated loss for the year. The standard also requires franchise or similar taxes partially based on income to be reported as income tax and the effects of enacted changes in tax laws or rates to be included in the annual effective tax rate computation from the date of enactment. The standard will be effective for the Company beginning January 1, 2022, with early adoption of the amendments permitted. The Company is currently evaluating the impact from the adoption of ASU 2019-12 on its consolidated financial statements Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or not significant to the condensed consolidated financial statements of the Company.

Revenues and Trade Receivable_2

Revenues and Trade Receivables, Net (Tables)	3 Months Ended
Revenues and Trade Receivables, Net (Tables)	Mar. 31, 2020
Revenues and Trade Receivables, Net [Abstract]
Revenue	The Company’s revenues were comprised of the following: Three Months Ended March 31, 2020 2019 Manufacture and supply revenue $ 6,916 $ 6,669 License and royalty revenue 426 4,622 Co-development and research fees 263 770 Proprietary product sales, net 1,160 582 Total revenues $ 8,765 $ 12,643
Disaggregation of Revenue	The following table provides disaggregated net revenue by geographic area: Three Months Ended March 31, 2020 2019 United States $ 7,506 $ 12,394 Ex-United States 1,259 249 Total revenues $ 8,765 $ 12,643
Trade and Other Receivables, Net	Trade and other receivables, net consist of the following: March 31, December 31, 2020 2019 Trade receivables $ 8,470 $ 9,094 Contract and other receivables 1,406 4,363 Less: allowance for bad debt (84 ) (124 ) Less: sales-related allowances (256 ) (203 ) Trade and other receivables, net $ 9,536 $ 13,130
Changes in Allowance for Bad Debt	The following table presents the changes in the allowance for bad debt: March 31, December 31, 2020 2019 Allowance for doubtful accounts at beginning of period $ 124 $ 58 (Reversals)/additions charged to bad debt expense (40 ) 66 Recoveries from amounts previously reserved -- — Allowance for doubtful accounts at end of period $ 84 $ 124
Sales Related Allowances and Accruals	The following table provides a summary of activity with respect to our sales related allowances and accruals for the three months ended March 31, 2020: Total Sales Related Allowances and Accruals Balance at December 31, 2019 $ 1,377 Provision related to sales during the period 1,157 Credits and payments (867 ) Balance at March 31, 2020 $ 1,667

Inventories, Net (Tables)

Inventories, Net (Tables)	3 Months Ended
Inventories, Net (Tables)	Mar. 31, 2020
Inventories, Net [Abstract]
Inventory, net	The components of Inventory, net is as follows: March 31, December 31, 2020 2019 Raw material $ 1,285 $ 1,244 Packaging material 1,101 1,096 Finished goods 701 519 Total inventories, net $ 3,087 $ 2,859

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
Property and Equipment, Net (Tables)	Mar. 31, 2020
Property and Equipment, Net [Abstract]
Property and Equipment, Net	March 31, December 31, Useful Lives 2020 2019 Machinery 3-15 yrs $ 21,088 $ 21,088 Furniture and fixtures 3-15 yrs 1,203 1,150 Leasehold improvements (a) 21,333 21,333 Computer, network equipment and software 3-7 yrs 2,790 2,787 Construction in progress 1,403 1,412 47,817 47,770 Less: accumulated depreciation and amortization (38,758 ) (38,044 ) Total property and equipment, net $ 9,059 $ 9,726 (a) Leasehold improvements are amortized over the shorter of the lease term or their estimated useful lives.

Right-of-Use Assets and Lease_2

Right-of-Use Assets and Lease Obligations (Tables)	3 Months Ended
Right-of-Use Assets and Lease Obligations (Tables)	Mar. 31, 2020
Right-of-Use Assets and Lease Obligations [Abstract]
Operating Lease Liabilities	Maturities of the Company’s operating lease liabilities are as follows: Remainder of 2020 $ 910 2021 1,287 2022 1,295 2023 944 2024 565 2025 565 2026 424 Total lease payments 5,990 Less: imputed interest (1,957 ) Total operating lease liabilities $ 4,033

Intangible Assets, Net and Ot_2

Intangible Assets, Net and Other Assets (Tables)	3 Months Ended
Intangible Assets, Net and Other Assets (Tables)	Mar. 31, 2020
Intangible Assets, Net and Other Assets [Abstract]
Components of Identifiable Intangible Assets	The following table provides the components of identifiable intangible assets, all of which are finite lived, and other assets: March 31, December 31, 2020 2019 Purchased technology-based intangible $ 2,358 $ 2,358 Purchased patent 509 509 2,867 2,867 Less: accumulated amortization (2,727 ) (2,714 ) Intangible assets, net 140 153 Other assets, primarily security deposits 288 286 Total Intangible assets, net and other assets $ 428 $ 439

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
Accounts Payable and Accrued Expenses (Tables)	Mar. 31, 2020
Accounts Payable and Accrued Expenses [Abstract]
Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following: March 31, December 31, 2020 2019 Accounts payable $ 10,283 $ 12,274 Accrued compensation 1,929 3,758 Real estate and personal property taxes 370 300 Accrued distribution expenses 1,411 1,174 Other 97 243 Total accounts payable and accrued expenses $ 14,090 $ 17,749

12.5% Senior Secured Notes an_2

12.5% Senior Secured Notes and Loans Payable (Tables)	3 Months Ended
12.5% Senior Secured Notes and Loans Payable (Tables)	Mar. 31, 2020
12.5% Senior Secured Notes and Loans Payable [Abstract]
Debt Maturity	A debt maturity table is presented below: Remainder of 2020 $ - 2021 3,500 2022 10,500 2023 17,500 2024 24,500 2025 14,000 Total $ 70,000

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
Net Loss Per Share (Tables)	Mar. 31, 2020
Net Loss Per Share [Abstract]
Basic and Diluted Net Loss Per Share	As a result of the Company’s net losses incurred for the three-month periods ended at March 31, 2020 and 2019, respectively, all potentially dilutive instruments outstanding would have anti-dilutive effects on per-share calculations for this period. Therefore, basic and diluted net loss per share were the same, as reflected below. Three Months Ended at March 31, 2020 2019 Numerator: Net loss $ (16,530 ) $ (14,726 ) Denominator: Weighted-average number of common shares – basic and diluted 33,569,694 24,963,603 Net loss per common share – basic and diluted $ (0.49 ) $ (0.59 )

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
Share-Based Compensation (Tables)	Mar. 31, 2020
Share-Based Compensation [Abstract]
Share-based Compensation Expense	The Company recognized share-based compensation in its Condensed Consolidated Statements of Operations and Comprehensive Loss during 2020 and 2019, respectively, as follows: Three Months Ended March 31, Expense classification: 2020 2019 Manufacture and supply $ 63 $ 44 Research and development 182 208 Selling, general and administrative 1,615 1,268 Total share-based compensation expenses $ 1,860 $ 1,520 Share-based compensation from: Restricted stock units $ 464 $ 463 Stock options 1,396 1,057 Employee stock purchase plan — — Total share-based compensation expenses $ 1,860 $ 1,520
Restricted Stock Units Awards	Restricted Stock Unit Awards (RSUs) Number of Units Weighted Average Grant Date Fair Value Per Share (In thousands) Unvested at December 31, 2019 74 $ 14.64 Granted — — Vested (30 ) 15.03 Forfeited — — Unvested at March 31, 2020 44 $ 14.38 Grant date fair value of shares vested during the period $ 448 Unrecognized compensation costs at March 31, 2020 $ 435
Stock Option Activity	Stock option awards Number of Options Weighted Average Exercise Price (In thousands) Outstanding at December 31, 2019 2,231 $ 10.42 Granted 716 $ 1.60 Exercised, Forfeited, Expired — Outstanding at March 31, 2020 2,947 $ 8.27 Vested or expected to vest at March 31, 2020 2,739 $ 8.28 Exercisable at March 31, 2020 666 $ 12.75
Valuation Assumptions for Determination of Fair Value of Options	The fair value of stock options granted were estimated using the Black-Scholes-Merton pricing model based upon the following assumptions: Three Months Ended March 31, 2020 Expected dividend yield None Expected volatility 100% Expected term (years) 6.1 Risk-free interest rate 0.6% - 1.7%

Corporate Organization and Co_2

Corporate Organization and Company Overview (Details) - USD ($) $ in Thousands	Dec. 17, 2019	Dec. 31, 2019
Equity Offering of Common Stock [Abstract]
Number of common shares issued (in shares)	8,050,000	8,050,000
Net proceeds from initial public offering	$ 37,835
Payments for deferred offering costs	2,415
Professional fees and other costs	$ 540

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Mar. 31, 2020
Recent Accounting Pronouncements [Abstract]
Operating lease right of use asset	$ 0	$ 3,912
Lease liabilities		$ 4,033
ASU 2016-02 [Member]
Recent Accounting Pronouncements [Abstract]
Operating lease right of use asset	4,224
Lease liabilities	$ 4,224
Incremental borrowing rate on lease payments	16.90%

Risks and Uncertainties (Detail

Risks and Uncertainties (Details) - USD ($) $ in Thousands	Dec. 17, 2019	Dec. 31, 2019	Jul. 31, 2019	Mar. 31, 2020	Jul. 15, 2019
Risks and Uncertainties [Abstract]
Working capital				$ 35,726
Cash and cash equivalents		$ 49,326		35,521
Debt Instrument, Interest Rate [Abstract]
Accumulated deficit		(130,474)		$ (147,004)
Additional fund amount			$ 52,226
Proceeds from refinancing of debt			$ 13,110
Common Stock issued upon warrant exercises		$ 1,821
Number of common shares issued (in shares)	8,050,000	8,050,000
Net proceeds from initial public offering		$ 37,295
Senior Secured Notes Due 2025 [Member]
Debt Instrument, Interest Rate [Abstract]
Interest rate				12.50%	12.50%
Accumulated deficit				$ (147,004)

Revenues and Trade Receivable_3

Revenues and Trade Receivables, Net, Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Contract with Customer, Asset and Liability [Abstract]
Invoices payable term	105 days
Contract assets	$ 1,458		$ 4,363
Contract liabilities	4,872		$ 5,154
Revenue [Abstract]
Total revenues	$ 8,765	$ 12,643
Minimum [Member]
Contract with Customer, Asset and Liability [Abstract]
Invoices payable term	30 days
Maximum [Member]
Contract with Customer, Asset and Liability [Abstract]
Invoices payable term	60 days
Manufacture and Supply Revenue [Member]
Revenue [Abstract]
Total revenues	$ 6,916	6,669
License and Royalty Revenue [Member]
Revenue [Abstract]
Total revenues	426	4,622
Co-Development and Research Fees [Member]
Revenue [Abstract]
Total revenues	263	770
Proprietary Product Sales, Net [Member]
Revenue [Abstract]
Total revenues	$ 1,160	$ 582

Revenues and Trade Receivable_4

Revenues and Trade Receivables, Net, Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues by Geographic Market [Abstract]
Total revenues	$ 8,765	$ 12,643
United States [Member]
Revenues by Geographic Market [Abstract]
Total revenues	7,506	12,394
Ex-United States [Member]
Revenues by Geographic Market [Abstract]
Total revenues	$ 1,259	$ 249

Revenues and Trade Receivable_5

Revenues and Trade Receivables, Net, Trade and other receivables, net (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Trade and other receivables, net [Abstract]
Trade receivables	$ 8,470	$ 9,094
Contract and other receivables	1,406	4,363
Less: allowance for bad debt	(84)	(124)	$ (58)
Less: sales-related allowances	(256)	(203)
Trade and other receivables, net	$ 9,536	$ 13,130

Revenues and Trade Receivable_6

Revenues and Trade Receivables, Net, Changes in Allowance for Bad Debt (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Allowance for Doubtful Accounts Receivable [Roll Forward]
Allowance for doubtful accounts at beginning of period	$ 124	$ 58
(Reversals)/additions charged to bad debt expense	(40)	66
Recoveries from amounts previously reserved	0	0
Allowance for doubtful accounts at end of the period	$ 84	$ 124

Revenues and Trade Receivable_7

Revenues and Trade Receivables, Net, Summary of Activity with Sales Related Allowances and Accruals (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Revenues and Trade Receivables, Net [Abstract]
Beginning balance	$ 1,377
Provision related to sales during the period	1,157
Credits and payments	(867)
Ending balance	1,667
Accrued balances - Trade and other receivables, net	256	$ 203
Accrued balances - Accounts payable and accrued expense	$ 1,411	$ 1,174

Revenues and Trade Receivable_8

Revenues and Trade Receivables, Net, Concentration of Major Customers (Details) - Indivior [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Revenue [Member]
Customer Concentration [Abstract]
Concentrations of risk	79.00%	86.00%
Receivables [Member]
Customer Concentration [Abstract]
Concentrations of risk	63.00%	80.00%

Material Agreements (Details)

Material Agreements (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		182 Months Ended	189 Months Ended
Material Agreements (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Mar. 31, 2020	Mar. 31, 2019	Feb. 20, 2019	Sep. 30, 2019
Commercial Exploitation Agreement with Indivior [Member]
Agreements [Abstract]
License agreement term		7 years
Automatic renewal period of agreement		1 year
Commercial Exploitation Agreement with Indivior [Member] \| Minimum [Member]
Agreements [Abstract]
Notice period of intent not to renew agreement		1 year
Supplemental Agreement with Indivior [Member]
Agreements [Abstract]
Contingent payments receivable in the future		$ 34,250
Revenues			$ 4,250	$ 40,750
Supplemental Agreement with Indivior [Member] \| Maximum [Member]
Agreements [Abstract]
Contingent payments receivable in the future		75,000
Supplemental Agreement with Indivior Performance or Event-Based Milestones [Member]
Agreements [Abstract]
Contingent payments receivable in the future		33,000
Supplemental Agreement with Indivior Additional Process Patent Rights to the Company [Member]
Agreements [Abstract]
Contingent payments receivable in the future		1,250
License Agreement with Sunovion Pharmaceuticals, Inc. [Member]
Agreements [Abstract]
Revenues		0	0		$ 18,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones [Member]
Agreements [Abstract]
Revenues					13,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones [Member] \| Maximum [Member]
Agreements [Abstract]
Contingent payments receivable in the future		45,000
License Agreement with Sunovion Pharmaceuticals, Inc. Upfront [Member]
Agreements [Abstract]
Revenues					$ 5,000
Agreement to Terminate CLA with KemPharm [Member]
Agreements [Abstract]
Revenues	$ 1,000	$ 0	$ 0
Percentage share of milestone payments paid	10.00%

Financial Instruments - Fair _2

Financial Instruments - Fair Value Measurements (Details) $ in Thousands	Mar. 31, 2020USD ($)
Level 2 [Member]
Fair Value of Financial Instruments [Abstract]
Assets, fair value	$ 0
Liabilities, fair value	0
Level 3 [Member]
Fair Value of Financial Instruments [Abstract]
Assets, fair value	0
Liabilities, fair value	$ 0

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventories, Net [Abstract]
Raw material	$ 1,285	$ 1,244
Packaging material	1,101	1,096
Finished goods	701	519
Total inventories, net	$ 3,087	$ 2,859

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Property and Equipment, Net [Abstract]
Property and equipment, gross		$ 47,817		$ 47,770
Less: accumulated depreciation and amortization		(38,758)		(38,044)
Total property and equipment, net		9,059		9,726
Property Plant and Equipment Income Statement Disclosures [Abstract]
Depreciation and amortization		714	$ 736
Machinery [Member]
Property and Equipment, Net [Abstract]
Property and equipment, gross		$ 21,088		21,088
Machinery [Member] \| Minimum [Member]
Property and Equipment, Net [Abstract]
Useful lives		3 years
Machinery [Member] \| Maximum [Member]
Property and Equipment, Net [Abstract]
Useful lives		15 years
Furniture and Fixtures [Member]
Property and Equipment, Net [Abstract]
Property and equipment, gross		$ 1,203		1,150
Furniture and Fixtures [Member] \| Minimum [Member]
Property and Equipment, Net [Abstract]
Useful lives		3 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property and Equipment, Net [Abstract]
Useful lives		15 years
Leasehold Improvements [Member]
Property and Equipment, Net [Abstract]
Property and equipment, gross	[1]	$ 21,333		21,333
Computer, Network Equipment and Software [Member]
Property and Equipment, Net [Abstract]
Property and equipment, gross		$ 2,790		2,787
Computer, Network Equipment and Software [Member] \| Minimum [Member]
Property and Equipment, Net [Abstract]
Useful lives		3 years
Computer, Network Equipment and Software [Member] \| Maximum [Member]
Property and Equipment, Net [Abstract]
Useful lives		7 years
Construction in Progress [Member]
Property and Equipment, Net [Abstract]
Property and equipment, gross		$ 1,403		$ 1,412

[1]	Leasehold improvements are amortized over the shorter of the lease term or their estimated useful lives.

Right-of-Use Assets and Lease_3

Right-of-Use Assets and Lease Obligations (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Lease, Cost [Abstract]
Estimated discount rate	16.90%
Operating lease expense	$ 442
Variable lease expense	106
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
Remainder of 2020	910
2021	1,287
2022	1,295
2023	944
2024	565
2025	565
2026	424
Total lease payments	5,990
Less: imputed interest	(1,957)
Total operating lease liabilities	$ 4,033
Minimum [Member]
Lease, Cost [Abstract]
Remaining lease term	3 years
Maximum [Member]
Lease, Cost [Abstract]
Remaining lease term	6 years 6 months

Intangible Assets, Net and Ot_3

Intangible Assets, Net and Other Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Identifiable Intangible Assets [Abstract]
Intangible assets, gross	$ 2,867		$ 2,867
Less: accumulated amortization	(2,727)		(2,714)
Intangible assets, net	140		153
Other assets, primarily security deposits	288		286
Total Intangible assets, net and other assets	428		439
Amortization expense	13	$ 13
Estimated Annual Amortization Expense [Abstract]
2020	50
2021	50
2022	50
Purchased Technology-based Intangible [Member]
Identifiable Intangible Assets [Abstract]
Intangible assets, gross	2,358		2,358
Purchased Patent [Member]
Identifiable Intangible Assets [Abstract]
Intangible assets, gross	$ 509		$ 509

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounts Payable and Accrued Expenses [Abstract]
Accounts payable	$ 10,283	$ 12,274
Accrued compensation	1,929	3,758
Real estate and personal property taxes	370	300
Accrued distribution expenses	1,411	1,174
Other	97	243
Total accounts payable and accrued expenses	$ 14,090	$ 17,749

12.5% Senior Secured Notes an_3

12.5% Senior Secured Notes and Loans Payable, 12.5% Senior Secured Notes (Details) $ / shares in Units, $ in Thousands, shares in Millions	Jul. 15, 2019USD ($)Tranche	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)
12.5% Senior Secured Notes [Abstract]
Warrants issued (in shares) \| shares		2
Warrant exercise price (in dollars per share) \| $ / shares		$ 0.001
Net proceeds from issuance of initial notes, warrants and first offer rights	$ 66,082
Debt Maturity [Abstract]
Remainder of 2020		$ 0
2021		3,500
2022		10,500
2023		17,500
2024		24,500
2025		14,000
Total		70,000
Amortization expense, deferred debt issuance costs and debt discounts		$ 584	$ 389
Perceptive Credit Opportunities Fund, LP [Member] \| Line of Credit [Member]
12.5% Senior Secured Notes [Abstract]
Payment of existing debt obligation	$ (56,340)
Debt maturity date		Dec. 16, 2020
Senior Secured Notes Due 2025 [Member]
12.5% Senior Secured Notes [Abstract]
Principal amount		$ 70,000
Interest rate	12.50%	12.50%
Warrants issued (in shares) \| shares		2
Warrant exercise price (in dollars per share) \| $ / shares		$ 4.25
Number of tranches \| Tranche	2
Frequency of periodic principal payment		quarterly
Debt maturity date		Jun. 30, 2025
Annual percentage increase in principal payments during first four quarters		10.00%
Annual percentage increase of initial loan principal payments during final four quarters		40.00%
Debt Maturity [Abstract]
Redemption percentage of debt under change of control provisions		101.00%
Amortization expense, deferred debt issuance costs and debt discounts		$ 584	$ 389
Unamortized deferred debt issuance cost and deferred debt discounts		$ 9,078		$ 9,662
Senior Secured Notes Due 2025 [Member] \| Minimum [Member]
Debt Maturity [Abstract]
Elective redemption percentage of debt		101.56%
Senior Secured Notes Due 2025 [Member] \| Maximum [Member]
12.5% Senior Secured Notes [Abstract]
Principal amount		$ 100,000
Additional borrowing capacity		$ 30,000
Debt Maturity [Abstract]
Elective redemption percentage of debt		112.50%
Asset based loans secured on second priority lien by receivables and inventory assets		$ 10,000
Senior Secured Notes Due 2025 - First Additional Offering [Member]
12.5% Senior Secured Notes [Abstract]
Additional borrowing capacity		10,000
Senior Secured Notes Due 2025 - First Additional Offering [Member] \| Maximum [Member]
Debt Maturity [Abstract]
Portion of proceeds used to monetize assets, if First Additional Offering has not been elected or funded		40,000
Senior Secured Notes Due 2025 - Second Additional Offering [Member]
12.5% Senior Secured Notes [Abstract]
Additional borrowing capacity		20,000
Senior Secured Notes Due 2025 - Second Additional Offering [Member] \| Maximum [Member]
Debt Maturity [Abstract]
Portion of proceeds used to monetize assets, if First Additional Offering has been elected and funded		$ 50,000

12.5% Senior Secured Notes an_4

12.5% Senior Secured Notes and Loans Payable, Perceptive (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Sep. 30, 2019
Line of Credit Facility [Abstract]
Loss on extinguishment of debt		$ (4,896)
Prepayment premiums paid		$ 2,944
Perceptive Credit Opportunities Fund, LP [Member] \| Line of Credit [Member]
Line of Credit Facility [Abstract]
Credit facility, maximum borrowing capacity	$ 50,000
Warrant to purchase senior common equity interest ratio to fully diluted common units	4.50%
Debt maturity date	Dec. 16, 2020

Warrants Issued to 12.5% Seni_2

Warrants Issued to 12.5% Senior Secured Noteholders (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 16, 2019	Mar. 31, 2020	Jul. 15, 2019
Warrants [Abstract]
Number of shares received upon automatic exercise of warrant (in shares)		2,000,000
Warrant exercise price (in dollars per share)		$ 0.001
Proceeds from warrant exercises	$ 1,821
Exercise of warrants (in shares)		0
Common Stock [Member]
Warrants [Abstract]
Common Stock issued upon warrant exercises (in shares)	428,571
Senior Secured Notes Due 2025 [Member]
Warrants [Abstract]
Interest rate		12.50%	12.50%
Debt maturity date		Jun. 30, 2025
Number of shares received upon automatic exercise of warrant (in shares)		2,000,000
Warrant exercise price (in dollars per share)		$ 4.25
Change in fair value of warrant		$ 6,800

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Numerator [Abstract]
Net loss	$ (16,530)	$ (14,726)
Denominator [Abstract]
Weighted-average number of common shares - basic and diluted (in shares)	33,569,694	24,963,603
Net loss per common share - basic and diluted (in dollars per share)	$ (0.49)	$ (0.59)
Stock Options [Member]
Dilutive Instruments [Abstract]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)	2,947,192	1,732,426
Unvested Restricted Stock Units [Member]
Dilutive Instruments [Abstract]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)	44,036	172,655
Warrants [Member]
Dilutive Instruments [Abstract]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)	1,571,429	0

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation expenses [Abstract]
Share-based compensation expenses	$ 1,860	$ 1,520
Manufacture and Supply [Member]
Share-based Compensation expenses [Abstract]
Share-based compensation expenses	63	44
Research and Development [Member]
Share-based Compensation expenses [Abstract]
Share-based compensation expenses	182	208
Selling, General and Administrative [Member]
Share-based Compensation expenses [Abstract]
Share-based compensation expenses	1,615	1,268
Restricted Stock Units [Member]
Share-based Compensation expenses [Abstract]
Share-based compensation expenses	$ 464	463
Number of Units [Roll Forward]
Unvested, at beginning of period (in shares)	74,000
Granted (in shares)	0
Vested (in shares)	(30,000)
Forfeited (in shares)	0
Unvested, at end of period (in shares)	44,000
Weighted Average Grant Date Fair Value Per Share [Abstract]
Unvested, at beginning of period (in dollars per share)	$ 14.64
Granted (in dollars per share)	0
Vested (in dollars per share)	15.03
Forfeited (in dollars per share)	0
Unvested, at end of period (in dollars per share)	$ 14.38
Grant date fair value of shares vested during the period	$ 448
Unrecognized compensation costs of RSU awards	$ 435
Compensation Cost Not yet Recognized [Abstract]
Unrecognized compensation cost, recognition period	2 years
Stock Options [Member]
Share-based Compensation expenses [Abstract]
Share-based compensation expenses	$ 1,396	1,057
Number of Options [Roll Forward]
Outstanding at beginning of period (in shares)	2,231,000
Granted (in shares)	716,000
Exercised, Forfeited, Expired (in shares)	0
Outstanding at end of period (in shares)	2,947,000
Vested or expected to vest at end of period (in shares)	2,739,000
Exercisable at end of period (in shares)	666,000
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 10.42
Granted (in dollars per share)	1.60
Outstanding at end of period (In dollars per share)	8.27
Vested or expected to vest at end of period (in dollars per share)	8.28
Exercisable at end of period (in dollars per share)	12.75
Weighted average grant date fair value (in dollars per share)	$ 1.26
Fair Value Assumptions [Abstract]
Expected dividend yield	0.00%
Expected volatility	100.00%
Expected term (years)	6 years 1 month 6 days
Additional Disclosures [Abstract]
Share price (in dollars per share)	$ 2.19
Intrinsic value of options granted	$ 456
Compensation Cost Not yet Recognized [Abstract]
Unrecognized compensation expenses related to non-vested stock options	$ 8,693
Unrecognized compensation cost, recognition period	2 years 1 month 6 days
Stock Options [Member] \| Minimum [Member]
Weighted Average Exercise Price [Abstract]
Granted (in dollars per share)	$ 1.54
Fair Value Assumptions [Abstract]
Risk-free interest rate	0.60%
Stock Options [Member] \| Maximum [Member]
Weighted Average Exercise Price [Abstract]
Granted (in dollars per share)	$ 4.17
Fair Value Assumptions [Abstract]
Risk-free interest rate	1.70%
Employee Stock Purchase Plan [Member]
Share-based Compensation expenses [Abstract]
Share-based compensation expenses	$ 0	$ 0
Employee Stock Purchase Plan [Abstract]
Purchase price of common stock as percentage of fair market value	85.00%
Shares issued under employee stock purchase plan (in shares)	0	0

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Income Taxes [Abstract]
Income tax benefit	$ 0	$ 0
Net (loss)/income before income taxes	$ (16,530)	$ (14,726)
Federal statutory tax rate	21.00%

Contingencies (Details)

Contingencies (Details)	1 Months Ended	3 Months Ended
Contingencies (Details)	Aug. 31, 2013Company	Mar. 31, 2020CasePatentStates
Litigation and Contingencies [Abstract]
Number of companies patent infringement lawsuits filed \| Company	6
Number of cases resolved		3
Number of additional infringement on patents \| Patent		2
Number of cases pending		3
Number of cases filed		4
Number of states in the antitrust litigation \| States		41

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event [Member] - PPP Loan [Member] $ in Millions	Apr. 17, 2020USD ($)
Federal Paycheck Protection Loan [Abstract]
Principal amount	$ 4.8
Interest rate	1.00%
Term of loan	2 years 6 months